Demonstrates metabolic changes in cervical cancer cells following melittin treatment, suggesting new therapeutic pathways.
Melittin-treated murine cervical cancer U14 cells have been widely recognized as a classic cellular model for anti-tumor research in cervical cancer. This article contains metabolomic data of U14 cell lysates from both melittin-treated and control groups. Untargeted metabolomic profiling was carried out by liquid chromatography-mass spectrometry (LC-MS) to systematically elucidate the global metabolic disturbances in cervical cancer cells upon melittin intervention. LC-MS raw data were processed for peak extraction and alignment using XCMS software, followed by quality control normalization with metaX software. Metabolite annotation was performed against the HMDB and KEGG databases as well as an in-house MS/MS spectral library, yielding metabolite feature data including mass-to-charge ratio (m/z), retention time (RT), and MS/MS-identified metabolites (MS2). A total of 22,976 metabolic ions were detected in this study, among which 16,176 were assigned Level 1 annotations and 1,114 were identified with high confidence at Level 2. All raw and processed data are publicly accessible at NGDC (accession number PRJCA065444). This untargeted LC-MS-based metabolomic dataset not only provides a comprehensive resource for elucidating metabolism-related anticancer mechanisms of melittin in murine U14 cervical cancer cells but also supports the development of targeted therapeutic strategies against cervical cancer.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: